Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | DHPS | P49366 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130797 | 1.00 | ACHE (0.49) | ACHEGRM5DHPSSIGMAR1DRD2 | |
| SCHEMBL29657194 | 0.84 | GRM5 (0.64) | ACHEGRM5DHPSSIGMAR1DRD2 | |
| SCHEMBL4116833 | 0.83 | NPC1 (0.43) | ACHEDRD2ALDH1A1MAPTMEN1 | |
| SCHEMBL4116828 | 0.83 | NPC1 (0.43) | ACHEDRD2ALDH1A1MAPTMEN1 | |
| SCHEMBL9305095 | 0.83 | DDB1 (0.49) | GRM5DHPSDDB1CRBNMEN1 | |
| SCHEMBL9305088 | 0.83 | DDB1 (0.49) | GRM5DHPSDDB1CRBNMEN1 | |
| SCHEMBL9306554 | 0.82 | DDB1 (0.48) | GRM5DHPSDDB1CRBNMEN1 | |
| SCHEMBL9306550 | 0.82 | DDB1 (0.48) | GRM5DHPSDDB1CRBNMEN1 | |
| SCHEMBL4116684 | 0.76 | BCAT2 (0.53) | DDB1CRBNALDH1A1MAPTKDM4E | |
| SCHEMBL31667202 | 0.76 | GRM5 (0.52) | ACHEGRM5DHPSSIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258302-B2 | Method for producing benzazepinone | API CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1985615-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | NISCH, GABBR1, GABBR2 | ACHE 979/4885GRM5 1154/4885DHPS 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.